How much funding has Loxo Oncology raised?

Loxo Oncology has raised $57.0M in total funding, most recently a Series B round.

Who are Loxo Oncology's investors?

Loxo Oncology's investors include Aisling Capital, Eli Lilly, New Enterprise Associates, OrbiMed.

When was Loxo Oncology founded?

Loxo Oncology was founded in 2013.

Where is Loxo Oncology headquartered?

Loxo Oncology is headquartered in United States.

What industry is Loxo Oncology in?

Loxo Oncology operates in Biotech, Oncology.

How many employees does Loxo Oncology have?

Loxo Oncology has 51-200 employees.

Loxo Oncology

Closed

United States · Founded 2013 · $57.0M raised

Biotech

Oncology

Employees: 51–200
Founded: 2013
Business Model: B2B
Website: loxooncology.com

Total Funding: $57.0M
Last Round: $24.0M Series BMay 2014
Rounds: 2

About

Loxo Oncology was a biopharmaceutical company focused on developing precision oncology medicines targeting cancers driven by specific genetic abnormalities. Its pipeline included larotrectinib (VITRAKVI), the first FDA-approved tumor-agnostic TRK inhibitor. The company was acquired by Eli Lilly in February 2019 for approximately $8 billion.

Summary

Loxo Oncology is a Biotech company based in United States, founded in 2013. It has raised $57.0M in total across 2 rounds, most recently a $24.0M Series B round in May 2014. Investors include Aisling Capital, Eli Lilly and New Enterprise Associates.